J. van Deutekom

1.4k total citations
25 papers, 1.1k citations indexed

About

J. van Deutekom is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, J. van Deutekom has authored 25 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 4 papers in Genetics and 3 papers in Genetics. Recurrent topics in J. van Deutekom's work include Muscle Physiology and Disorders (12 papers), RNA Interference and Gene Delivery (5 papers) and RNA Research and Splicing (4 papers). J. van Deutekom is often cited by papers focused on Muscle Physiology and Disorders (12 papers), RNA Interference and Gene Delivery (5 papers) and RNA Research and Splicing (4 papers). J. van Deutekom collaborates with scholars based in Netherlands, Belgium and Sweden. J. van Deutekom's co-authors include Annemieke Aartsma‐Rus, Gert‐Jan B. van Ommen, Jan J.G.M. Verschuuren, Johan T. den Dunnen, Ieke B. Ginjaar, Ivo F.A.C. Fokkema, Rune R. Frants, George W. Padberg, Annika Janson and Marja van Meijer and has published in prestigious journals such as PLoS ONE, Neurology and Journal of Virology.

In The Last Decade

J. van Deutekom

24 papers receiving 1.0k citations

Peers

J. van Deutekom
Danielle A. Griffin United States
Davide Gabellini Italy
Lavanya Bachaboina United States
Juliette Hordeaux United States
Jolanta Szulc Switzerland
Seemin Seher Ahmed United States
Thomas J. Fraites United States
Thibaut Marais France
Amy Poirier United States
Vinod Malik United States
Danielle A. Griffin United States
J. van Deutekom
Citations per year, relative to J. van Deutekom J. van Deutekom (= 1×) peers Danielle A. Griffin

Countries citing papers authored by J. van Deutekom

Since Specialization
Citations

This map shows the geographic impact of J. van Deutekom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. van Deutekom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. van Deutekom more than expected).

Fields of papers citing papers by J. van Deutekom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. van Deutekom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. van Deutekom. The network helps show where J. van Deutekom may publish in the future.

Co-authorship network of co-authors of J. van Deutekom

This figure shows the co-authorship network connecting the top 25 collaborators of J. van Deutekom. A scholar is included among the top collaborators of J. van Deutekom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. van Deutekom. J. van Deutekom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Putten, Maaike van, Chantal Beekman, Jukka Puoliväli, et al.. (2020). Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model. PLoS ONE. 15(12). e0244215–e0244215. 22 indexed citations
2.
Bosgra, Sieto, Jessica A. Sipkens, S. de Kimpe, et al.. (2019). The Pharmacokinetics of 2′- O -Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics. 29(6). 305–322. 22 indexed citations
3.
Aartsma‐Rus, Annemieke, Jennifer E. Morgan, Hendrik Neubert, et al.. (2019). Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. Journal of Neuromuscular Diseases. 6(1). 147–159. 44 indexed citations
4.
5.
Aartsma‐Rus, Annemieke, Peter A.C. ’t Hoen, Cor Breukel, et al.. (2013). Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Molecular Therapy — Nucleic Acids. 2. e66–e66. 17 indexed citations
6.
Ferlini, Alessandra, M. Tulinius, E. Niks, et al.. (2013). T.I.2 Exon skipping and PRO044 in Duchenne muscular dystrophy: Extending the program. Neuromuscular Disorders. 23(9-10). 847–847. 2 indexed citations
7.
Beekman, Chantal, Stavros Giannakopoulos, Jessica A. Sipkens, et al.. (2013). P.13.12 An objective method for immunofluorescence analysis of dystrophin levels in muscle from DMD patients in clinical studies. Neuromuscular Disorders. 23(9-10). 812–812. 2 indexed citations
8.
Veríssimo, Carla S., Jordi Carreras‐Puigvert, Yu Qin, et al.. (2012). Combining Doublecortin-Like Kinase Silencing and Vinca Alkaloids Results in a Synergistic Apoptotic Effect in Neuroblastoma Cells. Journal of Pharmacology and Experimental Therapeutics. 342(1). 119–130. 9 indexed citations
9.
Aartsma‐Rus, Annemieke, Anne Vroon, J. van Deutekom, et al.. (2012). Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. i75–i77. 7 indexed citations
10.
Heemskerk, Hans, et al.. (2012). Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models. Molecular Therapy — Nucleic Acids. 1. e44–e44. 30 indexed citations
11.
Wokke, Beatrijs, Sjoerd G. van Duinen, H.B. Ginjaar, et al.. (2012). G.P.76 Dystrophin levels do not influence disease progression in Becker muscular dystrophy patients with an exon 45–47 deletion. Neuromuscular Disorders. 22(9-10). 834–835. 2 indexed citations
12.
Falzarano, Maria Sofia, Chiara Passarelli, J. van Deutekom, et al.. (2012). T.P.22 Nanoparticles as delivery systems for antisense oligoribonucleotides: Biodistribution studies and definition of the release kinetic in treated mdx mice. Neuromuscular Disorders. 22(9-10). 859–859. 1 indexed citations
13.
Aartsma‐Rus, Annemieke, et al.. (2010). RNA-based therapeutics reaching the clinic. New Biotechnology. 27. S1–S1. 1 indexed citations
14.
Goemans, Nathalie, M. Tulinius, Gunnar Buyse, et al.. (2010). O.15 24 week follow-up data from a phase I/IIa extension study of PRO051/GSK2402968 in subjects with Duchenne muscular dystrophy. Neuromuscular Disorders. 20(9-10). 639–639. 6 indexed citations
15.
Heemskerk, Hans, Begoña Aguilera, Annika Janson, et al.. (2008). Muscle binding peptides found by phage display as delivery agent for antisense oligonucleotides. Journal of Controlled Release. 132(3). e3–e5. 2 indexed citations
16.
Deutekom, J. van. (1996). Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Human Molecular Genetics. 5(5). 581–590. 103 indexed citations
17.
18.
Tijssen, Marina A.J., Rita Shiang, J. van Deutekom, et al.. (1995). Molecular Genetic Reevaluation of the Dutch Hyperekplexia Family. Archives of Neurology. 52(6). 578–582. 42 indexed citations
19.
Frijns, Catharina J.M., J. van Deutekom, Rune R. Frants, & F.G.I. Jennekens. (1994). Dominant congenital benign spinal muscular atrophy. Muscle & Nerve. 17(2). 192–197. 26 indexed citations
20.
Bruyn, R.P.M., J. van Deutekom, Rune R. Frants, & George W. Padberg. (1993). Hereditary spastic paraparesis. Clinical Neurology and Neurosurgery. 95(2). 125–129. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danielle A. Griffin Breakdown of academic impact, for papers by Davide Gabellini Breakdown of academic impact, for papers by Lavanya Bachaboina Breakdown of academic impact, for papers by Juliette Hordeaux Breakdown of academic impact, for papers by Jolanta Szulc Breakdown of academic impact, for papers by Seemin Seher Ahmed Breakdown of academic impact, for papers by Thomas J. Fraites Breakdown of academic impact, for papers by Thibaut Marais Breakdown of academic impact, for papers by Amy Poirier Breakdown of academic impact, for papers by Vinod Malik
Rankless by CCL
2026